Mutant proline-and-arginine rich peptides and methods for using the same
US8030446B2 · kind B2 · utility
0Cited by
6References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 12, 2007 |
| Grant date | Oct 4, 2011 |
| Priority date | — |
| Expiry date | Apr 12, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/8107
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to mutant proline-and-arginine rich (PR) peptides with defined structural characteristics for use in inhibiting mammalian 20S proteasome activity and modulating expression of genes regulating the NF-κB pathway. Mutant PR peptides of the present invention differ from wild-type PR peptides by having at least one to three amino acid substitutions, wherein at least one of the amino acid residues at position one, two or three of the mutant PR peptide is positively charged.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.